B · Normal
[Hengrui Medicine: Many drugs are included in the National Reimbursement Catalog] On November 15th, Hengrui Medicine (600276.SH) announced that some of the company’s products were included in the National Reimbursement Catalog. Zelmetuxostat tablets, Ruzinora sodium tablets, and Hengpagliflozin and Regagliptin Metformin extended-release tablets (II) were included for the first time; new indications for Ruikang trastuzumab for injection were included; Dalcilil isethionate tablets were renewed with new indications; and 7 other drugs, including Proline Hengpagliflozin tablets, were successfully renewed. The total sales of the above-mentioned drugs in 2025 will be approximately 6.951 billion yuan, and the total sales in the first to third quarters of 2026 will be approximately 6.860 billion yuan. The National Medical Insurance Directory (2026) will be implemented on January 1, 2027.
A-share announcement express 🕐 2026-11-15 16:03

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet